Documentation of hip prostheses used in Norway: a critical review of the literature from 1996--2000.

Arild Aamodt, Lars Nordsletten, Leif I Havelin, Kari Indrekvam, Stein Erik Utvåg, Krystyna Hviding
{"title":"Documentation of hip prostheses used in Norway: a critical review of the literature from 1996--2000.","authors":"Arild Aamodt, Lars Nordsletten, Leif I Havelin, Kari Indrekvam, Stein Erik Utvåg, Krystyna Hviding","doi":"10.1080/00016470410004021","DOIUrl":null,"url":null,"abstract":"<p><p>We have conducted a systematic review of the scientific literature concerning outcome and clinical effectiveness of prostheses used for primary total hip replacement (THR) in Norway. The study is based on two Health Technology Assessment reports from the UK (Faulkner et al. 1998, Fitzpatrick et al. 1998), reviewing the literature from 1980 to 1995. Using a similar search strategy, we have evaluated the literature from 1996 through 2000. We included 129 scientific and medical publications which were assessed according to a specific appraisal protocol. The majority (72%) were observational studies, whereas only 9% were randomized studies. We could not retrieve any peer-reviewed documentation for one third of the implants. The Charnley prosthesis had by far the best and most comprehensive evidence base with better than 90% implant survival after about 10 years. Survival of the Charnley prosthesis declines by about 10% during each of the two following decades. Except for the Charnley and Lubinus IP, no other prosthesis on the market in Norway has given long-term results (> 15 years). 5 other cemented implants have given comparable results at about 10 years of follow-up. Some uncemented stems have shown promising medium-term outcome, but no combination of uncemented cup and stem fulfilled the benchmark criterion of > or = 90% implant survival at 10 years, which we propose as a minimum requirement for unrestricted clinical use for prostheses used in primary THR. New or undocumented implants should be introduced through a four-step model including preclinical testing, small series evaluated by radiosterometry, randomized clinical trial involving comparison with a well-documented prosthesis, and finally, surveillance of clinical use through registers.</p>","PeriodicalId":75403,"journal":{"name":"Acta orthopaedica Scandinavica","volume":"75 6","pages":"663-76"},"PeriodicalIF":0.0000,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta orthopaedica Scandinavica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/00016470410004021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We have conducted a systematic review of the scientific literature concerning outcome and clinical effectiveness of prostheses used for primary total hip replacement (THR) in Norway. The study is based on two Health Technology Assessment reports from the UK (Faulkner et al. 1998, Fitzpatrick et al. 1998), reviewing the literature from 1980 to 1995. Using a similar search strategy, we have evaluated the literature from 1996 through 2000. We included 129 scientific and medical publications which were assessed according to a specific appraisal protocol. The majority (72%) were observational studies, whereas only 9% were randomized studies. We could not retrieve any peer-reviewed documentation for one third of the implants. The Charnley prosthesis had by far the best and most comprehensive evidence base with better than 90% implant survival after about 10 years. Survival of the Charnley prosthesis declines by about 10% during each of the two following decades. Except for the Charnley and Lubinus IP, no other prosthesis on the market in Norway has given long-term results (> 15 years). 5 other cemented implants have given comparable results at about 10 years of follow-up. Some uncemented stems have shown promising medium-term outcome, but no combination of uncemented cup and stem fulfilled the benchmark criterion of > or = 90% implant survival at 10 years, which we propose as a minimum requirement for unrestricted clinical use for prostheses used in primary THR. New or undocumented implants should be introduced through a four-step model including preclinical testing, small series evaluated by radiosterometry, randomized clinical trial involving comparison with a well-documented prosthesis, and finally, surveillance of clinical use through registers.

在挪威使用的髋关节假体的文献:1996- 2000年的文献综述。
我们对挪威用于原发性全髋关节置换术(THR)的假体的结果和临床疗效的科学文献进行了系统回顾。该研究基于英国的两份健康技术评估报告(Faulkner et al. 1998, Fitzpatrick et al. 1998),回顾了1980年至1995年的文献。使用类似的搜索策略,我们评估了从1996年到2000年的文献。我们纳入了129份科学和医学出版物,根据特定的评估方案进行了评估。大多数(72%)是观察性研究,而只有9%是随机研究。我们找不到三分之一的植入物的同行评审文件。Charnley假体有目前最好和最全面的证据基础,10年后种植体存活率超过90%。在接下来的二十年里,Charnley假体的存活率每年下降10%左右。除了Charnley和Lubinus假体外,挪威市场上没有其他假体有长期效果(大约15年)。其他5个骨水泥植入物在大约10年的随访中也有类似的结果。一些未骨水泥假体的中期预后良好,但未骨水泥杯和假体的组合没有达到10年种植体存活率>或= 90%的基准标准,这是我们提出的用于原发性THR的假体不受限制临床使用的最低要求。新的或未记录的植入物应该通过四步模型引入,包括临床前测试,通过放射立体测量评估的小系列,随机临床试验,包括与记录良好的假体进行比较,最后通过注册来监督临床使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信